Carina Storrs
Freelance Writer
SFARI.org
From this contributor
Clinical research: Seizures common with 15q11-13 duplication
People with duplications of the 15q11-13 chromosomal region, which is linked to certain neurological disorders, can experience a variety of seizures, according to a study published 6 February in Epilepsia. They may also respond better to some seizure medications than others.
Clinical research: Seizures common with 15q11-13 duplication
Genetics: MicroRNA may suppress autism gene expression
A small fragment of RNA may regulate the expression of RORA, a gene implicated in many autism-related pathways, according to a study published 6 February in Scientific Reports.
Genetics: MicroRNA may suppress autism gene expression
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.